Tetrahydrocannabinol
The primary psychoactive cannabinoid with significant medical applications
Delta-9-tetrahydrocannabinol (THC) is the primary psychoactive compound in cannabis and the most pharmacologically studied cannabinoid. It has FDA-approved pharmaceutical forms (dronabinol, nabilone) and extensive clinical evidence for pain, nausea, appetite stimulation, and spasticity.
Primary Receptors & Targets
THC's psychoactive and therapeutic effects are primarily mediated through its action as a full agonist at CB1 receptors — G-protein coupled receptors concentrated in the brain's reward circuitry, hippocampus, cerebellum, and basal ganglia. CB1 activation inhibits adenylyl cyclase and modulates ion channels, ultimately reducing neurotransmitter release at synapses throughout the brain.
The euphoric effects of THC result from CB1 activation in the mesolimbic dopamine pathway — specifically, THC disinhibits dopamine neurons in the ventral tegmental area, producing dopamine release in the nucleus accumbens. This is the same pathway activated by other drugs of abuse, which explains THC's abuse potential.
THC's analgesic effects involve CB1 activation in pain-processing regions (periaqueductal gray, dorsal horn of the spinal cord) and peripheral CB1/CB2 receptors that modulate inflammatory pain. Its antiemetic effects involve CB1 activation in the dorsal vagal complex and nucleus tractus solitarius in the brainstem.
THC also has significant activity at CB2 receptors, which are concentrated in immune tissues and mediate anti-inflammatory effects without psychoactivity.
Multiple systematic reviews confirm efficacy; FDA-approved dronabinol (synthetic THC) for cancer pain.
FDA-approved dronabinol and nabilone; CB1 activation in brainstem suppresses vomiting reflex.
FDA-approved dronabinol; THC stimulates appetite via hypothalamic CB1 receptors.
Nabiximols (THC:CBD 1:1 oromucosal spray) approved in 30+ countries for MS spasticity.
Clinical data support reduction in nightmares and hyperarousal; THC modulates fear memory consolidation via CB1.
THC reduces intraocular pressure; short duration of action limits clinical utility vs. conventional treatments.
Reduces sleep onset latency and increases total sleep time; suppresses REM sleep with chronic use.
Evidence levels reflect the current state of clinical and preclinical research. Preliminary evidence does not constitute medical advice. Consult a healthcare provider before using cannabinoids therapeutically.
European Journal of Neurology
THC:CBD oromucosal spray reduced spasticity NRS scores by ≥30% in 74% of responders in a large multicenter trial.
Canadian Medical Association Journal
Smoked cannabis (9.4% THC) significantly reduced neuropathic pain intensity vs. placebo in a crossover RCT.
Annals of Internal Medicine
Dronabinol (synthetic THC) superior to prochlorperazine for chemotherapy-induced nausea in a multicenter RCT.
Neuropsychopharmacology
Low-dose THC facilitated extinction of fear memories in a PTSD-relevant model, suggesting therapeutic potential for trauma.
THC was first isolated and its structure fully characterized in 1964 by Israeli chemists Raphael Mechoulam and Yechiel Gaoni at the Hebrew University of Jerusalem. This was a landmark achievement — cannabis had been used medicinally for thousands of years, but the identity of its primary active compound had remained unknown. Mechoulam's subsequent work identifying the endocannabinoid system in the 1990s — including the discovery of anandamide and the CB1 and CB2 receptors — established the biological framework for understanding how THC and all cannabinoids produce their effects.
Average THC potency in cannabis products has increased dramatically over the past four decades. NIDA data shows average THC content in seized cannabis samples rose from approximately 4% in 1995 to over 12% by 2014. Contemporary dispensary flower commonly ranges from 18–30% THC, and concentrates can exceed 80–90%. This potency escalation has significant public health implications: the dose-response relationship for THC's adverse effects (anxiety, paranoia, psychosis risk) is steep, and products available today are pharmacologically very different from those used in older epidemiological studies.
Three THC-based pharmaceuticals have received FDA approval: Dronabinol (Marinol, Syndros) — synthetic delta-9-THC in sesame oil capsules or oral solution, approved for CINV and HIV/AIDS anorexia; Nabilone (Cesamet) — a synthetic THC analog, approved for CINV; and Nabiximols (Sativex) — a 1:1 THC:CBD oromucosal spray approved in 30+ countries for MS spasticity (not yet FDA-approved in the US). These pharmaceutical forms provide standardized dosing and quality control that is difficult to achieve with botanical cannabis products.